Another example is an anti-CL4 aptamer that inhibited triple-negative breast cancer (TNBC) cells and tumor growth by impacting the binding between epidermal growth factor receptor (EGFR) and integrin (Camorani et al., 2017). Here, EGFR is linked to neoplasm.